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Background: Diclofenac is a commonly used non steroidal anti-inflammatory drug 
(NSAID) for symptom control in osteoarthritis (OA) of the knee and soft tissue 
injuries. Although treatment with oral diclofenac is associated with serious adverse 
effects involving both the gastrointestinal and renal systems, these adverse effects are 
thought to be limited with topical diclofenac formulations without loss of efficacy. 
Objective: the aim of this review is to explore the available evidence in relation to the 
pharmacokinetics, efficacy and reported adverse effects of the topical diclofenac 
formulations available.  Results/conclusions: In the majority of studies examined, 
topical diclofenac formulations with sodium lotion, lecithin or epolamine gel, patch or 
plaster were either superior or equivalent to oral diclofenac formulations or placebo. 
Topical diclofenac significantly reduced pain and morning stiffness and improved 
physical function and patient global assessment without major adverse effects 
reported in patients with OA of the knee and provided significant pain relief in 
patients with sports and soft tissue injuries involving the ankle, knee or shoulder.  In 
the majority of studies reported the predominant adverse effect involved pruritus or 
rash at the site of application or nausea. The principle outcome of these studies is that 
topical diclofenac is a safe and practical alternative as a method of treatment in OA of 
the knee or as an alternative treatment for sports and soft tissue injury.  
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Introduction 
 
Historically NSAIDs have been used to assist the resolution of pain in conditions of 
OA of the knee and sports and soft tissue injuries. A major drawback of using oral 
forms of NSAIDs such as diclofenac is the high incidence of major adverse effects 
such as gastrointestinal bleeding, gastric ulceration and renal disease implications. 
The use of topical formulations of diclofenac is thought to be as efficacious as oral 
formulations without the risk of systemic side effects. Topical diclofenac is thought to 
reduce inflammation via inhibition of the COX 2 isoenzyme.  This review addresses 
the current evidence of the efficacy of topical formulations of diclofenac for treatment 
of OA of the knee and soft tissue and sports injury. 
  
Overview 
 
Musculoskeletal conditions range from intra articular disorders such as rheumatoid 
arthritis and osteoarthritis, injuries that involve simple ligaments such as sprains and 
extra articular joint disorders such as fibromyalgia and myofascial pain. In the UK, 
ankle sprains are a common soft tissue injury and occur in 53 per 10,000 population  
[1].By comparison osteoarthritis (OA) is a common joint disorder. Although 
radiographic evidence of OA is common in persons aged 65 years and over [2] often 
the severity of symptoms does not correlate well with pathogenic alterations viewed 
radiographically [3]. The knee joint is a common site for the development of OA [4]. 
Up to 11% of older people present with relevant clinical symptoms of OA of the knee 
along with variable forms of disability and long–term pain that requires symptom 
management [5]. It is postulated that OA will become a global cause of disability  in 
patients by the year 2020 [6]. 
 
OA is generally thought of as a disorder of middle–aged and older people. Commonly 
affected sites include: hip, knee and spine [7]. Typical symptoms include: joint pain in 
and around the joint site, morning stiffness lasting up to 30 minutes, loss of function, 
immobility and joint instability. Onset of symptoms is insidious. Pain is generally 
worse during motion and can be alleviated by rest. Patients with OA of the knee may 
complain of alterations to the gait and often experience a variety of forms of pain 
varying from a sharp pain to a dull constant ache [7]. 
  
Pain is a complex sensory process which is related to specific tissue damage. During 
trauma to the skin, blood vessels release inflammatory mediators such as 
prostaglandins, neuropeptides such as substance P and calictonin-gene related peptide. 
These substances act as a stimulus and cause peripheral nociceptor C and Aδ fibers to 
depolarize. This leads to the transmission of signals (signal transduction) via the 
dorsal horn to the cerebrum. During inflammation there is a hyperresponsive response 
whereby signal transmission to the dorsal horn does not require a stimulus. The 
hyperresponsive response can be controlled by NSAIDs [8].   
 
In OA of the knee the diagnostic classification criteria include: knee pain and 
osteophytes on X ray and at least one of the following: crepitus (irregularity of 
opposing cartilage surfaces) on motion, morning stiffness lasting 30 minutes and age 
over 50 years [9]. These additional characteristics are required because pathogenic 
changes on X ray may occur without the patient demonstrating symptoms of pain. 
 
The pathogenesis of OA is illustrated by degenerative changes to the articular 
cartilage of joints, new bone or osteophyte formation, loss of joint space between 
bone endings and sclerotic alterations to subchrondral bone. With the erosion of the 
articular cartilage, nociceptors become sensitized leading to chronic pain [10]. Pain 
can result from the stretching of the adjacent periosteum, growth of osteophytes, 
presence of microfractures, intraosseous pressure and synovitis [11]. The involvement 
of peri-articular tissues can also lead to joint pain, limitations in movement and 
disability [12,13]. Pain can arise from numerous sites; subchrondral bone, periosteum, 
joint capsule, synovial membrane, peri-articular muscles and ligaments.  
 
Numerous cytokines have been implicated in the pathogenesis of OA. Interleukin -1 
tumour necrosis factor þ are thought to activate enzymes associated with the 
proteolytic digestion of cartilage [14]. Insulin growth factor 1 and tissue growth factor 
þ may be involved in cartilage synthesis and repair processes [15]. OA develops when 
cartilage catabolism exceeds the process of cartilage synthesis. The cartilage catabolic 
process is maintained by several collagenolytic enzymes: 
 
•  Fibroblast collagenase 1 or matrix metalloproteinase -1 
•  Neutrophil collagenase2 or matrix metalloproteinase -2 
•  Collagenase 3. 
 
Treatment options include non-pharmacological and pharmacological approaches.  
Non-pharmacological approaches include weight reduction, exercise, patient 
education and joint support. Pharmacological approaches include the use of regular 
analgesics such as paracetamol to control pain and symptoms, if joint effusion is 
present patients may need intra-articular injections of corticosteroids. For 
uncontrolled pain and symptom control the recent EULAR recommendations suggest 
that Non Steroidal Anti-Inflammatory Drugs (NSAIDs) can be used as apart of pain 
management or patients with OA of the knee. NSAIDs can also be used to manage 
peri-articular and extra articular joint disorders such as tendinopathies and could also 
be used to treat fibromyalgia  [16].  
 
A drawback of using NSAIDs is the severity of side effects affecting the 
gastrointestinal tract, renal complications and cardiotoxicity. Topical NSAIDs are 
postulated to produce fewer side effects especially cardiac related effects and better 
tolerability [17] as they are able to reach the target site either via cutaneous 
penetration or systemic delivery [18]. Cutaneous delivery refers to the delivery of a 
drug to the site of application where the drug is able to target the peripheral nerves 
and soft tissues local to the site of application [19]. Although many reports indicate 
the benefits and efficacy of topical NSAIDs as anti-inflammatory agents and 
analgesics, these benefits are contested [20, 21]. 
 
Chemistry and pharmacokinetics properties  
 
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) and is a weak organic 
acids (pKa = 4.00). Although this chemical attribute helps the drug to accumulate in 
inflammed tissues and improves their effectiveness as anti-inflammatory agents [22] a 
number of formulations have been developed to improve cutaneous absorption. .  
 
The topical application of drugs is one of the oldest routes of drug delivery [19] as 
they can potentially achieve similar efficacy to oral formulations due to their ability to 
accumulate locally and achieve therapeutic concentrations without the risk of 
systemic side effects [23].  
It is established that the tissue absorption properties of topical NSAIDs are favourable 
with good penetration of the synovial fluid as well as superficial joints. This is 
evidenced by good cutaneous absorption at the site of application particularly when 
the formulation of diclofenac includes biocompatible lecithin organogels. As this 
component aids the absorption of the drug through keratinocytes to access non-
myelinated C-fibers and melanocytes of the epidermal layer and also access the 
cutaneous nociceptive fibers of the dermis.  In experimental studies. the efficacy of 
absorption was found to be dependent on the ability to be absorbed across the 
epidermal layers [24].  For good absorption, drugs need to ideally be of a low 
molecular weight (<500 Daltons), possess hydrophobic characteristics to traverse the 
stratum corneum and be sufficiently hydrophiliac to traverse the aqueous epidermis 
[18]. 
In clinical studies, the formulation of diclofenac employed can alter the rate of 
absorption through the use of enhancing agents such as dimethyl sulfoxide (DMSO) 
particularly with repeated dosing [25]. Newer topical formulations such as N-(2-
hydroxyethyl)-pyrrolidine Epolamine (DHEP) is an epolamine salt which is 
formulated as a plaster bioadhesive or lecithin enriched gel containing 1.3% DHEP 
which is more soluble in water and non-polar solvents compared to other 
formulations, its solubility properties allow the drug to interact with the cell 
membrane to promote its own absorption. penetration through the stratum corneum 
and concurrently carries hydrophobic and hydrophiliac drugs with improved 
cutaneous absorption [26, 27]. This salt prep unlike other topical preparations such as 
diclofenac sodium, does not require DMSO to improve cutaneous penetration [28]. 
Good cutaneous absorption rates of 6-7% of the dose administered can be achieved 
following repeated dosing with DHEP gel formulations with 1.32% or diclofenac 
diethylammonium 1.16%. The integrity of the skin, effects of the vehicle and impact 
of dehydration can alter absorption [29, 30]. The DHEP plaster is absorbed locally 
[31, 32] with the ability to penetrate into joint space and surrounding soft tissues [31, 
33]. It is suggested that the concentration difference of diclofenac DHEP in the 
synovial fluid was 30% of that found in the plasma at the same time point. Values 
were significantly different at p<0.05 level with 1.02 ±0.38 µg/L versus 
3.62±1.05µg/L [31]. However, the difference in drug concentration between the 
plasma and synovial fluid can be as high as 60-80% which may relate to the lower 
levels of albumin in synovial fluid compared to the plasma [34].  
Clinical studies also reported plasma concentration of DHEP of 15ng/mL versus 
1500ng/mL in plaster formulations and oral formulations respectively [28]. As the 
plasma concentration is low it is unlikely that the main therapeutic effect of DHEP is 
due to plasma drug concentrations but related to the ability of the drug to maintain 
high local concentrations in the peri-articular tissues [33]. These plasma concentration 
values concur with those achieved by other topical gel formulations [32] and are 
reported to peak concentrations within 1-2 hours following application [29]. Plasma 
levels of DHEP patch were also compared to equivalent levels (50 mgs) of oral 
voltarol;.1.7±0.9ng/mL and 1214±750ng/mL in DHEP patch and oral voltarol, 
respectively. In experimental studies, the elimination half life (t1/2) of diclofenac is 
about 3 times longer in synovial fluid compared to plasma [35]  and reaches a peak at 
3-4 hours after a single dose. The terminal half life of diclofenac in synovial fluid is 
round 5.2±1.1 hours. Steady state blood levels are reached after 4.5 days of drug 
administration [36]. The Cmax was10% of that achieved by a similar dose was 
administered intramuscularly 
Experimental evidence indicates that the depth of penetration of topical diclofenac 
measured using microdialysis probes assessed the interstitial concentrations in 
skeletal muscle compared to plasma. The mean Cmax was 18.75 ±4.97 µg/L in 
plasma compared to 219.68±66.36µg/L in interstitial skeletal muscle which is a 12 
fold difference and is a measure of the unbound drug fraction [37].  
In experimental studies, diclofenac is metabolized by cytochome P450 (CYP2C) and 
undergoes hydroxylation during phase 1 and conjugation with glucuronic acid to form 
metabolites either as conjugates or sulfates during phase 2. Up to 60-70% of 
metabolites are excreted in the urine [29] and up to 30% excreted in the bile. 
Although others indicate that 65% of the drug is excreted via the faecal route within 
0-72 hours [30, 38].  The evidence in support of metabolism and metabolic pathways 
is conflicting; this may be due to drug instability or the ability of spontaneous 
hydrolysis of glucuro-conjugated metabolites to reform the parent compound [29].     
 
Clinical efficacy 
There are a number of topical diclofenac preparations available for use in patients 
with OA of knee, hip or ankle or soft tissue injury. These include: sprays, gel, patch, 
bioadhesive plaster or lotion. Each product has been assessed and compared with oral 
forms of diclofenac or similar or alterative formulations [36,39, 40].  Several studies 
have shown the therapeutic benefits of topical diclofenac and its role in pain 
management where sufficient concentrations of diclofenac is distributed to the target 
tissue and in so doing produces a therapeutic effect. There are currently a range of 
published studies, meta-analyses and systematic reviews, and working party 
recommendations that have explored the use of topical diclofenac as part of pain 
management for patients with OA of the knee [41-47], sports injury [19], soft tissue 
injury [36, 48-50], actinic ketatoses [51] and acute migraine attacks [52].  Key studies 
are identified in Table 1.for OA of the knee and Table 2 for sports injury studies and 
meta-analyses. 
 
Randomised clinical trials focused on OA of the knee 
Various formulations of topical diclofenac have been assessed in patients with OA of 
the knee. Bioadhesive plasters impregnated with DHEP have been shown to relieve 
pain during rest and improve movement and joint function in patients being treated 
for OA of the knee [28].  
 
In RCTs involving patients with OA of the knee, 1.5% topical diclofenac induced a 
significant reduction in pain relief, morning stiffness and improvement in functional 
mobility and patient global assessment in patients in durations of 4 week [43], 6 week 
[42] and 12 week trials [46] compared to placebo.  In these studies, minor skin 
dryness was a common complaint in 36-39% of patients. In 5-6% of patients skin 
dryness lead to discontinuation of treatment [42, 46]. More serious gastrointestinal 
complaints were limited and cardiovascular side effects were not evaluated.  
A drawback of published RCTs is the duration; longer trials e.g. studies greater than 
12 weeks are needed that compare a larger spectrum of conditions related to acute and 
chronic pain in patients with OA of the knee.  
 
Meta-analyses of RCTS in OA. 
Several meta-analyses have shown that topical NSAIDs such as diclofenac can reduce 
the symptoms of pain associated with OA of the knee over a period of two weeks [41, 
53].  In a recent 6 week study of 622 patients with OA of the knee topical 1.5% 
diclofenac solution provided equivalent pain relief as oral 50 mg diclofenac capsules. 
Side effects were reported, topical diclofenac solution contains DMSO which is 
metabolized to dimethyl sulfone and dimethyl sulfide which causes a garlic like 
aroma / taste which can be offensive for patients. In addition, topical diclofenac 
caused dry skin in 27% of patients with 5% of patients experiencing a vesculobullous 
rash and significantly fewer gastrointestinal problems compared to oral diclofenac 
[41].  Patients receiving placebo also DMSO also experienced a rash at the site of 
application.         
 
However contrasting findings are reported [45]. A recent recent meta-analysis of RCT 
oppose this view [45]. The pooled treatment effect of topical diclofenac compared to 
placebo in terms of pain relief was 0.41 (95% CI, 0.16- -0.66) for week 1 and 0.4 
(95%, CI 0.15-0.65) for week 2. Topical diclofenac was superior to placebo only for 
the first two weeks of treatment. The data do not support the view that topical 
diclofenac is superior to oral drug forms in terms of pain relief or improvements in 
functional mobility and the authors call for a review of current guidelines for the 
management of OA of the knee, [44, 57]. However a pooled analysis of 2 RCTs 
involving 235 patients with OA comparing DHEP plaster containing 180 mg of 
diclofenac to placebo [28, 40] and a meta-analysis of RCTs [41] suggest that topical 
diclofenac is advantageous as a drug of choice in patients with OA of the knee.  
 
Soft tissue injury RCTs and experimental studies 
The efficacy of topical diclofenac preparations have been assessed in patients 
presenting with soft tissue injuries, often for short durations. Recently it was reported 
that topical diclofenac prescribed QID for 14 days also led to significant reductions in  
pain  on forced dorsiflexion in patients with lateral epicondylitis [54].   
 
The effectiveness of diclofenac has been tested using different preparations. In an 
RCT, the efficacy of diclofenac pyrrolidine gel was compared to similar formulations 
with the addition of lecithin to treat mild-to-moderate post traumatic knee, ankle and 
muscle injuries [55]. Efficacy and safety data were collected in relation to 
measurements of pain on movement. In the first 3 days, the group receiving 
diclofenac pyrrolidine gel plus lecithin recorded significantly reduced pain compared 
to diclofenac pyrrolidine gel only. By day 10 of the study, the difference between 
groups was statistically significant. Findings indicate that the addition of lecithin to 
diclofenac pyrrolidine gel increases its pain relieving capability to produce a 
significant and more rapid therapeutic response compared to diclofenac pyrrolidine 
gel alone.  
 
The benefits of the addition of lecithin to DHEP formulations has also been shown in  
patients with shoulder periarthritis and lateral epicondylitis. Findings showed a 
significant reduction in pain measured in mm by visual analogue scales (VAS);-
33.2±26.1mm in DHEP lecithin group compared to -21.2.±18.8.mm in placebo [27].   
 
Recently the use of bioadhesive DHEP plaster was assessed in patients with soft 
tissue injuries. The plaster significantly reduced pain intensity as measured by the 
Huskisson’s visual analogue scale (VAS) by 59.9% compared to placebo 29.9%. 
DHEP displayed similar efficacy to oral forms of diclofenac. It is also suggested that 
after the removal of DHEP plaster the duration of pain relief may extend up to 96 
hours [56]. 
 
Similar studies in patients with sports and soft tissue injury have reported favourable 
results [19, 50]. Both studies used topical diclofenac patches either containing either 
140 mgs diclofenac sodium or 1.3% DHEP to provide pain relief compared to gelatin 
only placebo. In a two week study a visual analogue scale was used to measure pain 
intensity. Two hundred and thirteen patients with minor sports injuries were involved. 
Significant reductions in pain intensity were found compared to placebo on day 3 
(p0.036) and day 14 (p0.048) [19]. Side effects reported included signs of pruritus in 
5% of patients and 17% of placebo patients and gastrointestinal affects involving 6% 
or nausea involving 10% of patients in both drug and placebo groups.  
 
In a similar study, 120 patients with acute impact injuries following injury involving a 
blunt instrument reported significant pain relief (p<0.0001) within 3 days of treatment 
using diclofenac patch compared to placebo [50]. Measurements such as tenderness, 
pressure and time for resolution of pain were taken over a period of 7 days [50]. 
Resolution of symptoms occurred in 73% of (n=87) patients recovered within 7 days  
compared to 6.7% of the placebo group (n=8). Tolerability of topical diclofenac was 
very good with <10% of patients reporting side effects such as rash, pruritus.  
 
Meta-analyses involving soft tissue injury 
In a recent review of 19 RCTs, the efficacy of topical diclofenac as an anti-
inflammatory drug used in the management of pain was examined in 3000 patients 
with a history of OA and soft tissue injury [39]. Findings show that the application of 
topical diclofenac led to a reduction in pain intensity and inflammation in both 
chronic and acute conditions comparable to oral formulations of diclofenac and 
NSAIDs (ibuprofen, naproxen) as well as changes in mobility and functional capacity. 
Topical diclofenac was superior to placebo. In terms of safety and tolerability, topical 
diclofenac was associated with fewer side effects compared to oral forms and other 
NSAIDs, reports of mild skin irritation was noted [39].  
 
Pharmacodynamics  
 
Evidence from clinical and pharmacological studies imply that diclofenac exerts its 
actions by inhibiting cycloxygenase (COX) enzyme. There are two forms of the COX 
enzyme; COX-1 is associated with gastric epithelium; COX-2 is responsible for 
prostaglandin synthesis. Inhibition of COX-2 reduces the production of inflammatory 
mediators such as prostaglandins [51, 58], interleukin-6 and substance P. It is also 
suggested that diclofenac can alter G-protein mediated signal transduction pathways 
[19] and exerts an enhanced effect on hyperalgic muscle by directly interacting with 
nociceceptors [56].  
 Additional properties of diclofenac relate to the inhibition of murine angiogenesis and 
murine colonic adenocarcinoma [59] and collagenolytic and keratolytic effects [60].  
 
Safety and tolerability 
One of the drawback of using diclofenac as part of a pain management programme is 
the reports of adverse effects such as gastrointestinal bleeding, small bowel injury, 
upper and lower gastrointestinal harm and acute renal failure [61], anaemia [41]. The 
use of DHEP and diclofenac sodium patches are efficacious as a method of pain relief 
without the problems of systematic exposure [36, 50] and accompanying adverse side 
effects.  In the studies available, the possible cardiac effects of topical diclofenac has 
not been reported or evaluated.  
 
In more recent trials, topical 1% diclofenac gel was found to be efficacious in 
maintaining pain relief and improving physical function in patients with OA of the 
hand and knee [62, 63]. Although some studies were of short duration they offer 
additional findings regarding the use of gel preparations [63]. In this study topical 
diclofenac was well tolerated with up to 48% of patients reported the drug as good or 
excellent in the management of their pain. Findings from a recent trial indicates that 
DHEP patch significantly reduced pain in patients with sports., localized strains and 
sprains with limited side effects reported [49]. 
 
 A recent meta-analysis indicates that only 2.3% of patients administering DHEP 
developed mild cutaneous side effects such as urticaria and rash [28]. These findings 
contrast with a recent meta-analysis that reported that up to 15-20% of patients treated 
with topical NSAIDs experienced similar cutaneous side effects including pruritus 
[45]. This higher incidence concurs with published data particularly regarding the 
safety and tolerability data involving older people [64, 65]. 
 
Conclusions 
Current studies indicate that topical diclofenac is a safe, well tolerated and efficacious 
option as a mode of treatment for resolution of pain in patients with OA knee or sports 
and soft tissue injury. These conclusions are mainly developed from studies that were 
of a duration greater than 2 weeks. One meta-analyses of shorter duration failed to 
support this view; this difference in opinion may be due to the formulation or 
excipient used.  
 
Expert opinion 
Topical diclofenac has been used to treat a number of soft tissue injuries and OA of 
the knee in patients who require both short-term and long-term pain relief but also 
need improvements in functional mobility. Numerous topical formulations of 
diclofenac are available, of those that incorporate lecithin, they appear to offer 
additional benefits in terms of cutaneous delivery, ability to concentrate in the 
synovial fluid compared to oral formulations and offer significant pain relief.  Patients 
benefit from the application of topical diclofenac compared to oral administration in 
terms of ease of application and reduced systemic effects with only minor cutaneous 
adverse effects reported. Evidence from RCTs and meta-analyses support the view 
that topically applied diclofenac is comparable or better than oral formulations with 
regard to the ability to provide sustained pain relief and improve mobility. Medical 
and non-medical prescribers should be encouraged to use topical diclofenac 
formulated with lecithin as a treatment option. 
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Table 1. Characteristics of RCTs and meta-analyses involving OA of the knee 
 
PARAMETERS BAER BOOKMAN ROTH  TUGWELL KILMINSTER  
Study RCT RCT RCT RCT RCT 
Duration 6 weeks 4 weeks 12weeks 12 weeks 1 week 
Sample 216 248 326 622 43 
Drug 1.5% 
dic. Na 
1.5% dic Na 1.5% 
dic Na 
1.5% dic 
Na vs oral 
dic. 
Dic. spray 35 
mgs compared 
to 1% dic gel 
Pain relief 
reduction 
-5.2vs 
3.3. p= 
0.002 
-3.9 vs -2.5 
p=0.023 
-7.1 vs -
5.6. 
p=0.02 
44% dic na  
vs49 % oral 
dic. 
Spray had  a 
faster onset of 
action 
compared to 
gel 
Physical 
function 
Improvement 
-13.4vs 
-6.9 p= 
0.01 
-11.6vs -8.4, 
p=0.023 
-18.5 vs 
-14.3 
p=0.04  
39% dic na  
vs46 % oral 
dic.3 
NA 
Stiffness 
improvement 
-1.8 vs -
0.9 
p=0.002 
-1.5 vs -0.7 
p=0.003 
-2.3 vs -
1.6 
p=0.02 
39% dic na  
vs45 % oral 
dic. 
NA 
PGA 
improvement 
-1.3 vs -
0.7  
p=0.001 
-6.7vs 7.8 
p0.039 
-1.5 vs -
1.2 
p=0.06 
43% dic na  
vs49 % oral 
dic. 
NA 
Side effects Dry 
skin in 
39% of 
cases 
Dry skin in 
36% of 
cases 
Dry skin 
in 
36.6% 
of cases 
Dry skin in 
27% of 
1.5% Dic 
Na cases 
Pennesaid 
was as 
effective as 
oral dic.  
No reported 
adverse effects 
Reference no      
 
 
Dic Na refers to diclofenac sodium solution. 
Oral dic. Refers to 50 mg oral diclofenac capsules  
Pain, physical function and stiffness were assessed using the WOMAC  LK3.1 OA 
index criteria measured on a 5 –point  likert scale where 0 indicates none, 1 indicates 
mild, 2 indicates moderate, 3 indicates severe and 4 indicates extreme. 
 PGA refers to physical general assessment measured using a visual analogue scale 
from   very good (0) to extreme (4). 
 
 
 
 
 
 
 
Table 2. RCTs and meta–analyses of topical diclofenac use in soft tissue injuries and 
other uses  
 
REF STUDY 
POPULATION 
TREATMENT  
REGIMEN 
EFFICACY ADVERSE  
EFFECTS 
COMMENTS 
Galer  213 patients  
with history of 
sprain, strain or 
contusion of 
less than 72 
hours aged 18-
75 years 
 2 week study 
patients 
randomized to 
either DHEP 
patch solution 
or placebo 
Pain 
reduction 
(p0.003) at 
3 days and 
(p=0.036) at 
14 days  
compared to 
placebo 
Nausea  and 
GI effects 6-
10%, of 
cases; 
pruritus in 5 
% of  cases 
DHEP patch 
was 
efficacious in 
reducing pain 
following 
sports related 
injury 
without major 
side effects  
Predel 120 patients 
with a history 
of trauma with 
a blunt 
instrument 
1 week study 
randomized to 
140 mg dic. 
patch within 3 
hours of injury 
or placebo 
patch with 
identical 
excipient 
73.3% of 
cases 
reported a 
reduction in  
pain  on 
motion and 
at rest   
compared to 
placebo 
(p=0.0001)  
10% of cases 
reported 
minor 
pruritus or 
rash in both 
placebo and 
drug group 
Tolerability 
of dic. patch 
was very  
good 
Carr 418 patients, 
aged 18-65  
years with 
history of knee, 
ankle or foot 
contusion , 
sprain, or strain  
Patients 
randomized to 
DHEP patch 
or placebo 
57.8% of 
patients 
treated with 
DHEP 
patch 
showed a 
pain 
reduction 
within 3 
days 
compared to 
placebo 
7.9% of drug 
group and 
5.8% of 
placebo 
group 
reported 
cutaneous 
reactions at 
the site of 
application   
Dic. patch 
was rated as 
good to 
excellent in 
ability to 
reduce pain  
Spacca 158 patients 
with history of 
shoulder pain 
10 days cycle  
of treatment 
with DHEP 
lecithin gel or 
Pain was 
significantly 
reduced by 
DHEP gel 
No major side 
effects 
reported. 
DHEP 
lecithin gel 
was effective 
in reducing 
placebo  by day 3 
(p<0.001)  
pain for 
patients with 
shoulder pain 
Mahler 100 patients 
with mild to 
moderate post 
traumatic 
injuries to 
knee, ankle or 
muscle injury 
Randomised to 
either DHEP 
gel or DHEP 
lecithin.   
Pain on 
movement 
was better 
with DHEP 
lecithin 
treatment at 
both 3 and 
10 days post 
treatment 
(p=0.036). 
Both groups 
tolerated the 
treatments 
well with no 
reported 
adverse 
effects 
DHEP 
lecithin is 
superior to 
DHEP gel as 
a method of 
pain relief for 
shoulder pain 
Towheed Meta analysis 
of 4 RCTs 
involving 1412 
patients mean 
duration of 
studies 8.5 
weeks 
 Patients were 
randomized to 
dic.sodium 
with DMSO 
lotion 
compared to 
placebo or oral 
diclofenac 
Dic. sodium 
lotion 
significantly 
improved 
pain, 
physical 
function 
and PGA 
and was 
superior in 
comparison 
to placebo. 
All RCTs 
reported 
minor skin 
irritation as a 
side effect 
from 
application  
of diclofenac. 
sodium lotion 
Diclofenac 
sodium is an 
effective 
topical 
NSAID is a 
safe 
alternative for 
treatment of 
OA of knee. 
Brulmann Pooled 
analyses of 2  
14 day RCTs  
involving 235 
patients with 
OA knee.  
Patients  aged 
18-85 years 
with OA knee 
were 
randomized to 
either DHEP 
plaster or 
placebo plaster 
59.5 % of 
patients 
receiving 
DHEP 
plaster 
reported  a 
reduction in 
pain 
intensity 
compared to 
29.9% of 
placebo 
group   
Good 
tolerability to 
the plaster 
was reported 
in both 
groups. 2.3% 
of patients 
reported rash 
or urticaria on 
application of 
the plaster 
DHEP plaster 
is efficacious 
and safe as a 
mode of 
short-term 
treatment for 
OA knee. 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
